Kaleido Biosciences, Inc.
KLDO
$0.002
$0.00191,900.00%
OTC PK
| 12/31/2021 | 09/30/2021 | 06/30/2021 | 03/31/2021 | 12/31/2020 | |
|---|---|---|---|---|---|
| Revenue | 102.47% | -78.42% | -15.60% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 102.47% | -78.42% | -15.60% | -- | -- |
| Cost of Revenue | 8.62% | 11.19% | 37.40% | 30.81% | -77.68% |
| Gross Profit | -7.00% | -14.03% | -38.46% | -28.55% | 78.06% |
| SG&A Expenses | -11.30% | -29.09% | 4.07% | -7.72% | 6.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -175.13% | -- | -- | -- | -- |
| Total Operating Expenses | 1.57% | -1.50% | 27.33% | 18.85% | 4.03% |
| Operating Income | -0.31% | -0.16% | -27.92% | -17.29% | -2.75% |
| Income Before Tax | -1.28% | 0.20% | -26.25% | -17.86% | -2.58% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.28% | 0.20% | -26.25% | -17.86% | -2.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.28% | 0.20% | -26.25% | -17.86% | -2.58% |
| EBIT | -0.31% | -0.16% | -27.92% | -17.29% | -2.75% |
| EBITDA | -0.11% | 0.49% | -27.80% | -16.52% | -1.68% |
| EPS Basic | 14.45% | 16.66% | 5.37% | 9.93% | 14.20% |
| Normalized Basic EPS | 14.47% | 16.65% | 5.39% | 9.93% | 11.57% |
| EPS Diluted | 14.45% | 16.66% | 5.37% | 9.93% | 14.20% |
| Normalized Diluted EPS | 14.47% | 16.65% | 5.39% | 9.93% | 11.57% |
| Average Basic Shares Outstanding | 18.39% | 19.75% | 33.43% | 30.85% | 19.57% |
| Average Diluted Shares Outstanding | 18.39% | 19.75% | 33.43% | 30.85% | 19.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |